Efficacy of the combination of MEK and CDK4/6 inhibitors<i>in vitro</i>and<i>in vivo</i>in KRAS mutant colorectal cancer models
Michael S. Lee(UNC Lineberger Comprehensive Cancer Center), Scott Kopetz(The University of Texas MD Anderson Cancer Center)
Cited by 126
Related Papers
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.4k